# GPT-5.4 (R2) Review

**Role:** External referee review
**Model:** openai/gpt-5.4
**Paper:** paper.pdf
**Timestamp:** 2026-03-09T02:59:52.057419
**Route:** OpenRouter + LaTeX
**Review mode:** Tri-model (3 independent reviewers)
**Tokens:** 18628 in / 4804 out
**Response SHA256:** 5eca2c0be1b4f6d1

---

This paper asks an important and policy-relevant question: whether ERPO (“red flag”) laws reduce total suicide mortality or merely shift deaths across methods. The paper’s main substantive contribution is to revisit the ERPO-suicide question using a heterogeneity-robust staggered DiD estimator rather than naive TWFE, and the sign reversal between TWFE and Callaway–Sant’Anna (CS) is potentially important. The paper is clearly motivated, transparent about some limitations, and commendably does not overstate the main null on total suicide.

That said, in its current form I do not think the paper is publication-ready for a top field/general-interest outlet. The central concerns are (i) identification of an ERPO-specific causal effect in the presence of contemporaneous bundled firearm-policy changes and a major 2018 data break, (ii) unresolved pre-trend problems, and (iii) invalid or at least not-yet-credible inference for the short-panel mechanism results, which are currently reported with conventional significance stars despite the paper itself acknowledging the standard errors are implausible. These are substantive issues, not presentational ones.

## 1. Identification and empirical design

### A. Main identification claim is not yet credible as an ERPO-specific causal effect
The paper’s causal language often refers to “the effect of ERPO adoption” on suicide, but the design as implemented does not isolate ERPOs from broader post-Parkland gun policy bundles. The paper itself acknowledges this in the limitations section (“bundled-policy confounding is the most important unresolved threat,” Section 6.5), and I agree. But this is too central to be relegated to a limitation.

The 2018–2020 adoption wave was not random policy timing. In many states, ERPOs were enacted together with other firearm or public-safety legislation, and often amid post-Parkland political mobilization. If concurrent policies also affect suicide (waiting periods, background checks, storage laws, domestic-violence firearm restrictions, etc.), the ATT cannot be interpreted as ERPO-specific absent explicit controls, event-specific coding, or a design that narrows to “clean” adoptions.

This is particularly important because the paper’s main contribution is substantive, not purely methodological. If the estimand is really “adoption of an ERPO-containing package,” the title and interpretation need to reflect that.

**Concrete issue:** Section 6.5 admits the ATT may be a bundled-policy effect, but the abstract, introduction, conclusion, and tables continue to frame the estimate as “ERPO adoption.” That is too strong.

### B. The 2018 data gap is more consequential than the paper allows
The combined panel omits 2018 because one source ends in 2017 and the other begins in 2019 (Section 3.1, 3.4). This is especially problematic because **eight states adopt in 2018**, i.e., the single largest cohort. For those states, there is no treatment-year observation and no way to observe immediate treatment dynamics or treatment-year shocks. The paper states that CS-DiD “does not require consecutive years,” which is true mechanically, but that does not solve the substantive issue: for the most important cohort, treatment occurs exactly at the seam between two data systems and an omitted calendar year.

Excluding the 2018 cohort is presented as a robustness check, but that does not fully address the concern because:
1. the baseline estimate still heavily relies on those states;
2. the excluded-cohort estimate becomes much less precise and somewhat larger (0.43 vs 0.24), suggesting sensitivity;
3. the data-source break and treatment timing are confounded for the key adoption wave.

This is not fatal by itself, but it substantially weakens publication readiness.

### C. Parallel trends are not established
The paper repeatedly gives a relatively reassuring verbal summary of pre-trends, but the actual evidence is substantially weaker.

- Section 5.2 states that a pre-treatment coefficient at event time -5 falls outside the 95% band.
- The same section says a “conservative diagonal Wald test rejects joint significance of the pre-treatment coefficients.”
- Appendix B (“Pre-Trend Analysis”) reports that the average absolute pre-treatment coefficient is approximately **0.56**, which is more than twice the main ATT of **0.24**.
- Section 6.5 says the average absolute pre-treatment coefficient is **0.18**, not 0.56. That contradiction must be resolved.

This is not a minor discrepancy. If the pre-period coefficients are of similar or larger magnitude than the estimated treatment effect, then the design does not convincingly distinguish treatment from pre-existing differential evolution. The paper’s current interpretation—“likely idiosyncratic variation rather than a systematic trend”—is too dismissive relative to the evidence presented.

At minimum, the paper needs more disciplined pre-trend diagnostics, and likely an “honest” sensitivity analysis to violations of parallel trends rather than relying on visual inspection and pointwise bands.

### D. No-anticipation is asserted, not demonstrated
The no-anticipation assumption is plausible in some settings, but here it is not trivial. ERPO adoption often followed highly salient legislative and media processes. Awareness, enforcement preparation, law-enforcement behavior, or related prevention responses could begin before statutory effective dates. This matters especially for the 2018 wave after Parkland. The paper should do more than state that “individual suicide decisions are unlikely to respond to pending legislation” (Section 4.1). That may be true for individuals, but anticipatory institutional behavior is also relevant.

### E. Treatment heterogeneity is correctly recognized, but the implementation does not fully leverage it
A binary treatment indicator is likely too coarse given the paper’s own emphasis on massive utilization heterogeneity across states. The paper’s conclusion that “adoption has no detectable aggregate effect” may just mean “average adoption with highly variable and often low utilization has no detectable effect.” That is a substantively narrower claim than the framing suggests.

This is not necessarily a design flaw if carefully interpreted, but it limits the paper’s contribution unless the authors can bring in utilization intensity or institutional heterogeneity.

## 2. Inference and statistical validity

This is the most serious area needing revision.

### A. Inference for the mechanism decomposition is not credible as reported
The paper explicitly notes, in footnote 1 of Section 5.1, that the standard errors in the short-panel mechanism decomposition are implausible, especially for non-firearm suicide (SE = 0.018 with only 9 treated states). I agree. Once the paper itself recognizes the SEs are likely severely understated, it is not acceptable to continue presenting Columns (2)–(4) of Table 2 with significance stars and discussing them as statistically significant effects.

This is a major statistical-validity problem. Those columns should either:
- be removed from the main table,
- be clearly relabeled as descriptive/exploratory without p-values/stars,
- or be re-estimated with valid small-sample inference.

As currently presented, Table 2 materially overstates evidentiary strength.

### B. State-clustered inference may be acceptable for the long panel, but the short-panel design is far too thin for conventional asymptotics
For the 1999–2024 combined panel with ~50 clusters, state clustering may be serviceable. For the 2019–2024 short panel with only 9 treated states and 2–4 post periods per cohort, inference is much less reliable. This is especially true for aggregated CS estimates, where influence-function asymptotics may behave poorly in small samples and with sparse treatment timing.

The paper mentions randomization inference or wild bootstrap but then proceeds without them. For a paper whose central claims rely on valid inference, that is not sufficient.

### C. Event-study inference relies on pointwise confidence intervals
The event-study figures use pointwise 95% confidence intervals. For pre-trend assessment and dynamic claims, simultaneous confidence bands are the more appropriate benchmark. Pointwise bands are known to overstate how reassuring pre-trends look. Given the already problematic pre-trend evidence, the paper should not rely on pointwise visual inspection.

### D. Sample sizes are reported, but cohort support and effective identifying variation are not
The paper reports total N, but for staggered DiD the more important quantity is support by cohort and event time. In particular:
- how many state-years identify each event-time coefficient?
- how many treated states contribute to each relative time?
- what is the composition of controls for each cohort under each control-group choice?

Without this, the dynamic results are difficult to evaluate, particularly around distant leads/lags.

### E. The power discussion is internally inconsistent
Section 4.6 says the design can detect effects on the order of 0.8–1.5 per 100,000 with 80% power, but then says the 95% CI “effectively rules out effects larger than 0.64 per 100,000.” That latter statement uses the upper endpoint of the CI on a positive estimate and is not the relevant quantity for ruling out reductions. Elsewhere the paper correctly says the CI rules out reductions larger than 0.16. These statements are inconsistent and need correction.

More broadly, the power section is too casual for a paper emphasizing null results. If the claim is that the null is informative, the minimum detectable effect should be derived more carefully and tied to policy-relevant benchmarks.

## 3. Robustness and alternative explanations

### A. Robustness checks are useful but do not address the biggest threats
The checks on not-yet-treated controls, leave-one-out, excluding anti-ERPO states, and excluding the 2018 cohort are all reasonable. However, they are not targeted at the most important alternative explanations:
1. concurrent firearm-policy packages;
2. differential pre-trends;
3. pandemic-era shocks in the short panel;
4. data-source seam between 2017 and 2019.

The paper needs robustness exercises that directly address those issues.

### B. The placebo outcome is weakly diagnostic
Drug overdose is an imperfect placebo here. State-level overdose mortality moved dramatically and heterogeneously during the opioid/fentanyl crisis and COVID period; it is a noisy test for shared confounding. An insignificant estimate with a very wide CI does not provide strong reassurance. Moreover, some unobserved crisis-related factors could affect both suicide and overdose differently across states. I would not put much weight on this placebo.

A better placebo strategy would use outcomes more plausibly unaffected by ERPOs but driven by similar reporting systems and state-level public-health conditions, or placebo treatment dates / pseudo-adoption exercises.

### C. Mechanism claims are appropriately qualified in text, but the table presentation undermines that caution
The paper says the mechanism decomposition is “inconclusive,” which is the right bottom line. But the table shows significant positive firearm and non-firearm effects. Those stars will inevitably be read as evidence. The text and presentation are currently in tension.

### D. External validity boundaries are interesting but underdeveloped
The observation that adopting states are disproportionately low-gun-ownership states is important. If ERPOs are more likely to matter where firearm access is high, the average ATT among adopters may be an attenuated estimate of broader policy potential. This is a useful point, but it remains speculative because the paper does not systematically analyze heterogeneity by baseline gun prevalence, rurality, or prior firearm suicide share. The failed subgroup exercise is informative, but the paper could do more with continuous interactions or cohort-level descriptives.

## 4. Contribution and literature positioning

### A. The methodological contribution is real
The clearest contribution is showing that naive TWFE and heterogeneity-robust staggered DiD produce qualitatively different answers in this setting. That is useful, and potentially publishable in a policy outlet if the rest of the design were tightened.

### B. The substantive contribution relative to prior ERPO work is less secure
The paper says it is the first heterogeneity-robust staggered DiD application to the ERPO-suicide question using the longest available panel. That may be true, and it is useful. But to reach top-journal publication readiness, the paper would need a more compelling substantive design or much stronger evidence that prior positive findings are artifacts of methodological bias rather than differences in estimand, scale, or implementation.

### C. Important methodological references should be added or integrated more centrally
The paper cites several modern DiD papers, but the literature positioning should more clearly engage:

- **Sun and Abraham (2021)** on event-study contamination in staggered adoption settings.
- **Borusyak, Jaravel, and Spiess (2024)** as an alternative heterogeneity-robust estimator and useful cross-check.
- **Roth (2022)/Roth et al.** on pre-trend testing limitations and “Honest DiD” style sensitivity.
- Possibly **Freyaldenhoven, Hansen, and Shapiro (2019)** on using unaffected outcomes/proxies to diagnose confounding trends, if relevant.

On the policy side, the paper should more systematically engage work on contemporaneous firearm policy environments and policy bundles, not only ERPO-specific papers.

## 5. Results interpretation and claim calibration

### A. The main total-suicide conclusion is reasonably calibrated
The paper’s main conclusion—no statistically detectable effect of ERPO adoption on total suicide at the state-year level—is mostly appropriately phrased. The distinction between adoption and utilization is well made.

### B. But some claims are still too strong given the identification problems
Statements like “ERPO adoption has not detectably reduced population-level suicide mortality” are fair as a description of this design’s estimate, but not yet as a broad causal conclusion. Given unresolved bundled-policy confounding and pre-trend concerns, the paper should say that the study does not find robust evidence of a reduction in aggregate suicide rates following ERPO adoption in this panel, rather than implying the design identifies the causal ERPO effect cleanly.

### C. The paper’s treatment of TWFE needs more caution
The sign reversal is interesting, but the paper sometimes overstates what it demonstrates. Because the Goodman-Bacon decomposition is conducted on a restricted 2005–2017 subpanel, it does **not** explain the full-sample TWFE estimate. The text does mention this, but the interpretive tone still leans too heavily on “this illustrates TWFE bias.” It illustrates possible bias, not a complete forensic decomposition of the reported sign flip.

### D. There are factual/quantitative inconsistencies that need correction
A few examples:
- Average absolute pre-trend coefficient is reported as **0.18** in Section 6.5 and **0.56** in Appendix B.
- Power discussion mixes detectable effect sizes and CI interpretation inconsistently.
- Table 2 reports highly significant short-panel mechanism estimates while text says inference is likely unreliable.

These inconsistencies materially affect how readers interpret the strength of evidence.

## 6. Actionable revision requests

### 1. Must-fix issues before acceptance

#### 1. Rework inference for the short-panel mechanism results
- **Issue:** Table 2 Columns (2)–(4) report significance using standard errors the paper itself says are implausibly small.
- **Why it matters:** Invalid inference is disqualifying. Readers cannot be asked to trust p-values that the paper itself disavows.
- **Concrete fix:** Remove significance stars and p-value-based language for the short-panel mechanism estimates unless you can provide credible small-sample inference (e.g., randomization/permutation inference tailored to staggered adoption, wild bootstrap where valid, or a design-specific resampling approach). If that is not possible, move these estimates to an appendix and present them strictly as descriptive/exploratory.

#### 2. Address the pre-trend problem directly and transparently
- **Issue:** Pre-treatment coefficients are not reassuring; a lead is significant, joint tests reject, and the reported average absolute lead magnitude is inconsistent across sections.
- **Why it matters:** Parallel trends is the key identifying assumption. As written, evidence against it is stronger than the paper admits.
- **Concrete fix:** Recompute and consistently report all pre-trend statistics; present cohort/event-time support; use simultaneous bands; add a sensitivity analysis to bounded violations of parallel trends (e.g., HonestDiD-style or related approach). Rewrite the discussion to reflect what the diagnostics actually show.

#### 3. Clarify and, if possible, narrow the causal estimand given bundled-policy confounding
- **Issue:** The ATT likely captures ERPO adoption bundled with other contemporaneous firearm policies.
- **Why it matters:** Without this, the headline causal claim is overstated.
- **Concrete fix:** Ideally include controls for major concurrent firearm-policy changes using RAND or another policy database, or restrict to cleaner adoptions. If policy controls are infeasible, explicitly redefine the estimand throughout as the effect of ERPO adoption in the observed state policy environment, not an ERPO-specific causal effect.

#### 4. Reassess the treatment of the 2018 cohort and data-source seam
- **Issue:** The largest adoption cohort occurs exactly in the omitted year and at the splice between two sources.
- **Why it matters:** This threatens both measurement comparability and timing interpretation.
- **Concrete fix:** Provide much fuller evidence on source comparability; explore alternative ways to harmonize a continuous series if possible; report cohort-specific results that isolate how much the baseline estimate depends on the 2018 adopters; consider making a specification excluding the 2018 cohort a co-equal main result rather than a secondary check.

### 2. High-value improvements

#### 5. Add alternative heterogeneity-robust estimators as cross-checks
- **Issue:** The main result relies almost entirely on one implementation of CS-DiD.
- **Why it matters:** Replication across estimators would materially strengthen credibility.
- **Concrete fix:** Re-estimate core specifications using Sun-Abraham and/or Borusyak-Jaravel-Spiess estimators and compare aggregate/event-study results.

#### 6. Provide fuller cohort/event-time support and weighting diagnostics
- **Issue:** It is hard to assess which cohorts and event times identify the results.
- **Why it matters:** Sparse support can make aggregated estimates misleading.
- **Concrete fix:** Add a table/appendix showing cohort sizes, available pre/post periods, and the number of treated states contributing to each dynamic coefficient.

#### 7. Strengthen placebo/falsification exercises
- **Issue:** Drug overdose is a weak placebo in this context.
- **Why it matters:** Current placebo evidence does not strongly reassure against confounding.
- **Concrete fix:** Add placebo adoption dates, pseudo-treated states, or alternative outcomes less entangled with pandemic/opioid dynamics; if possible, examine pre-policy outcomes that should not move under ERPOs but share similar data structure.

#### 8. Calibrate the null more carefully
- **Issue:** The paper sometimes shifts between “no detectable effect,” “rules out large effects,” and “insufficient implementation intensity.”
- **Why it matters:** Publication readiness depends on a disciplined interpretation of what effect sizes are policy-relevant and what the design can rule out.
- **Concrete fix:** Replace the informal power paragraph with a clearer minimum-detectable-effect or equivalence-style discussion tied to plausible aggregate impacts implied by utilization rates.

### 3. Optional polish

#### 9. Tighten the role of the TWFE comparison
- **Issue:** The paper may overinterpret the sign reversal.
- **Why it matters:** The methodological lesson is useful, but should not outrun the evidence.
- **Concrete fix:** Frame TWFE as a diagnostic contrast, not as a fully explained bias decomposition; be explicit that the restricted Goodman-Bacon exercise is illustrative only.

#### 10. Better integrate the adoption/utilization distinction
- **Issue:** One of the paper’s best insights is that adoption may be too weak a treatment to detect aggregate effects.
- **Why it matters:** This distinction helps reconcile null aggregate findings with positive individual-level evidence.
- **Concrete fix:** Bring utilization intensity into the framing earlier and, if any cross-state utilization data can be assembled, add even a limited heterogeneity/descriptive analysis.

## 7. Overall assessment

### Key strengths
- Important question with clear policy relevance.
- Correctly rejects naive reliance on TWFE in a staggered-adoption setting.
- Transparent about several limitations.
- Main null result on total suicide is, in tone, more careful than many papers in this literature.
- Distinction between law adoption and actual utilization is insightful and potentially important.

### Critical weaknesses
- ERPO-specific identification is not credible without addressing bundled contemporaneous firearm-policy changes.
- Pre-trends are more problematic than the paper acknowledges.
- Inference for the short-panel mechanism results is not valid as presented.
- The 2018 omitted year/data-source seam is a major design complication because it coincides with the largest treatment cohort.
- Several quantitative inconsistencies undermine confidence in the empirical implementation.

### Publishability after revision
I think the paper is potentially salvageable, especially for a strong policy field journal, if it is reframed more modestly and the inferential/identification issues are addressed seriously. But in its current form it is not ready for publication. The most important necessary changes are to fix the short-panel inference, confront the pre-trend evidence honestly, and either address or explicitly narrow away from ERPO-specific causal claims under bundled-policy confounding.

DECISION: MAJOR REVISION